Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for mRNA-4157/V940 +KEYTRUDA in Cancer, Non-small cell lung carcinoma. The expected timing is based on the latest available company guidance and may change.
Partnered w/ Merck. Ph3 INTerpath-002 trial - Global recruitment begun. First patients enrolled in Australia. 5/22/24- Study design presentation at ASCO '24 on June 1st. 10/28/24 Initiate INTerpath-009 trial. 2/14/25- Ph3 currently enrolling. 11/06/25:- Two NSCLC Ph3 INTerpath studies continue enrolling. New randomized Ph2 first-line metastatic squamous NSCLC study launched.
Verification
Confirm timing and program details against the company announcement or filing.